The Clyde Biosciences team are delighted to have been shortlisted for an award in February’s Scottish Life Sciences Awards. One of three finalists in the Innovative Collaboration award, Clyde has been recognised for its contribution to a global initiative designed to improve the way drugs are assessed for cardiac safety. The initiative, known as CiPA […]
Clyde Biosciences has been recognised in The Scotsman newspaper (December 1, 2017) as a leading innovator in Scottish life sciences. Alongside other Scottish companies, Clyde was noted for its recent project with AstraZeneca examining the effects of certain drug compounds on cardiac cells. Clyde’s unique optical cell function assay service provides information to biotech and […]
Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration with Abbvie) AbbVie SPS FINAL Measurements of voltage, intracellular […]
Clyde Biosciences Presents Four Posters at SPS 2017 Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration […]
Recent Publication Highlights Flexibility and Power of Clyde’s CellOPTIQ® Assay Highlights Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital and is only available […]
WELCOME TO OUR NEW WEBSITE Clyde Biosciences is delighted to launch our new website. Have a good look around and please get in touch with feedback or inquiries.
Clyde Biosciences Autumn Business Update Highlights CiPA 28 study finished and data submitted weeks ahead of schedule New CellOPTIQ®-X contractility assay launched New Heart Failure model launched Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important […]
NEWHOUSE – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in animal requirements Accurate prediction of the human response Reduction in later stage attrition Heart cell […]
Clyde Biosciences is delighted to announce the appointment of Alan Johnston to the post of Chair. Alan brings a wealth of CRO experience to Clyde. He spent some 30 years with Inveresk Research (subsequently Charles River Laboratories) in Edinburgh, Alan had several Senior Management posts within Inversek and had responsibility for Commercial staff. He is now Trustee […]
Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. Clyde Biosciences, a spin-out company from the University of Glasgow, […]